The Ledger

JNJ

Johnson & JohnsonHealth Caresp500

Last close $225.54May 11, 2026

Day +1.86%

Everything we've seen

·May 12, 4:02 PMstreamnews
2 Dividend Stocks That Are No-Brainer Buys in May
Markets are on the rise, but worries about a recession remain elevated as May gets underway.
·May 12, 4:02 PMstreamnews
Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
·May 12, 4:02 PMstreamnews
Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
·May 12, 4:02 PMstreamnews
Johnson & Johnson (JNJ) Highlights Strong Phase 3 Results for TREMFYA Across Dosing Regimens
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Johnson & Johnson is among the best cancer stocks. TheFly reported on May 5 that JNJ released Phase 3 FUZION study results evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At 24 weeks, the therapy showed […]
·May 12, 4:02 PMstreamnews
Assessing Johnson & Johnson (JNJ) Valuation After Recent Pullback And Conflicting Fair Value Signals
Recent performance snapshot for Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but down about 1% over the past week and 7% over the past month. Over the past 3 months the share price is also down about 7%, even as the stock shows a total return of about 48% over the past year and around 50% across the past 3 and 5 years. See our latest analysis for Johnson & Johnson. The recent 7% decline in the...
·May 12, 4:02 PMstreamnews
Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter For Improved Deliverability, Enhanced Lesion Crossing And New Repositioning Capabilities For Calcified CAD Treatment
Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioningShockwave C2 Aero enables clinicians to
·May 12, 4:02 PMstreamnews
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vital to utilize analytical tools for strategic decisions and capitalize on evolving market dynamics.Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" directory has been added to Resear
·May 12, 4:02 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
·May 12, 4:02 PMstreamnews
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif., May 12, 2026--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
·May 12, 4:02 PMstreamnews
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
·May 12, 4:02 PMstreamnews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
·May 12, 4:02 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
·May 12, 4:02 PMstreamnews
S&P 500, Nasdaq under pressure as chip stocks see red
US stocks (^DJI, ^IXIC, ^GSPC) are mixed ahead of Tuesday's market close as the Nasdaq Composite drops by over 1%, pushed lower by declines in chip stocks. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the market reaction to the April Consumer Price Index (CPI) report released this morning.
·May 12, 4:01 PMstreamnews
2 Dividend Stocks That Are No-Brainer Buys in May
Markets are on the rise, but worries about a recession remain elevated as May gets underway.
·May 12, 4:01 PMstreamnews
Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
·May 12, 4:01 PMstreamnews
Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
·May 12, 4:01 PMstreamnews
Johnson & Johnson (JNJ) Highlights Strong Phase 3 Results for TREMFYA Across Dosing Regimens
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Johnson & Johnson is among the best cancer stocks. TheFly reported on May 5 that JNJ released Phase 3 FUZION study results evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At 24 weeks, the therapy showed […]
·May 12, 4:01 PMstreamnews
Assessing Johnson & Johnson (JNJ) Valuation After Recent Pullback And Conflicting Fair Value Signals
Recent performance snapshot for Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but down about 1% over the past week and 7% over the past month. Over the past 3 months the share price is also down about 7%, even as the stock shows a total return of about 48% over the past year and around 50% across the past 3 and 5 years. See our latest analysis for Johnson & Johnson. The recent 7% decline in the...
·May 12, 4:01 PMstreamnews
Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter For Improved Deliverability, Enhanced Lesion Crossing And New Repositioning Capabilities For Calcified CAD Treatment
Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioningShockwave C2 Aero enables clinicians to
·May 12, 4:01 PMstreamnews
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vital to utilize analytical tools for strategic decisions and capitalize on evolving market dynamics.Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" directory has been added to Resear
·May 12, 4:01 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
·May 12, 4:01 PMstreamnews
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif., May 12, 2026--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
·May 12, 4:01 PMstreamnews
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
·May 12, 4:01 PMstreamnews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
·May 12, 4:01 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
·May 12, 4:01 PMstreamnews
S&P 500, Nasdaq under pressure as chip stocks see red
US stocks (^DJI, ^IXIC, ^GSPC) are mixed ahead of Tuesday's market close as the Nasdaq Composite drops by over 1%, pushed lower by declines in chip stocks. Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the market reaction to the April Consumer Price Index (CPI) report released this morning.
·May 12, 3:50 PMstreamnews
2 Dividend Stocks That Are No-Brainer Buys in May
Markets are on the rise, but worries about a recession remain elevated as May gets underway.
·May 12, 3:50 PMstreamnews
Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
·May 12, 3:50 PMstreamnews
Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
·May 12, 3:50 PMstreamnews
Johnson & Johnson (JNJ) Highlights Strong Phase 3 Results for TREMFYA Across Dosing Regimens
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Johnson & Johnson is among the best cancer stocks. TheFly reported on May 5 that JNJ released Phase 3 FUZION study results evaluating TREMFYA in adults with active perianal fistulizing Crohn’s disease. At 24 weeks, the therapy showed […]
·May 12, 3:50 PMstreamnews
Assessing Johnson & Johnson (JNJ) Valuation After Recent Pullback And Conflicting Fair Value Signals
Recent performance snapshot for Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) has held relatively steady in the very short term, with the stock roughly flat over the past day but down about 1% over the past week and 7% over the past month. Over the past 3 months the share price is also down about 7%, even as the stock shows a total return of about 48% over the past year and around 50% across the past 3 and 5 years. See our latest analysis for Johnson & Johnson. The recent 7% decline in the...
·May 12, 3:50 PMstreamnews
Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter For Improved Deliverability, Enhanced Lesion Crossing And New Repositioning Capabilities For Calcified CAD Treatment
Next-generation intravascular lithotripsy (IVL) catheter resets physicians' expectations by addressing unmet needs in deliverability, lesion crossing and balloon repositioningShockwave C2 Aero enables clinicians to
·May 12, 3:50 PMstreamnews
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
Bi/multispecific drugs in oncology present key opportunities: precision targeting, innovative immune modulation, and personalized therapies. With rapid pipeline growth, breakthrough approvals, and rising investment, it’s vital to utilize analytical tools for strategic decisions and capitalize on evolving market dynamics.Dublin, May 12, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Bi/Multispecific Drug in the Oncology Market with Confidence" directory has been added to Resear
·May 12, 3:50 PMstreamnews
Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) and JPMorgan Nasdaq Equity Premium Income ETF (NYSEARCA:JEPQ) pull from very different stock universes. JEPI leans on S&P 500 names with a covered call overlay. JEPQ runs the same income playbook on the Nasdaq-100. The latest fact sheets show why that distinction matters in 2026. Defensive Blue Chips Anchor ... Why JPMorgan Equity Premium Income ETF Limits Upside While JPMorgan Nasdaq Equity Premium Income ETF Sacrifices Growth for 11.98% Yields
·May 12, 3:50 PMstreamnews
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif., May 12, 2026--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
·May 12, 3:50 PMstreamnews
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
·May 12, 3:50 PMstreamnews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
·May 12, 3:50 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
·May 12, 3:48 PMstreamnews
Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
SANTA CLARA, Calif., May 12, 2026--Johnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave™ C2 Aero Coronary IVL Catheter
·May 12, 3:48 PMstreamnews
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales
BAYRY beats Q1 earnings estimates as Crop Science sales rise, while Nubeqa and Kerendia gains help offset declines in Xarelto and Eylea.
·May 12, 3:48 PMstreamnews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
·May 12, 3:48 PMstreamnews
Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy
JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.
?May 12, 1:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
JNJ has moved up 2.38% with no identifiable headline catalyst driving the move, suggesting this could be a gap or sector rotation rather than a sustained fundamental shift. The macro context (elevated 5Y inflation breakevens at 1.9σ above trend) favors commodity and inflation-sensitive sectors like Energy and Gold, not healthcare defensives like JNJ — this could even act as a mild headwind for continuation. With 135 minutes remaining and no clear catalyst to sustain momentum, mean-reversion risk is elevated and confidence in continuation is low.
!May 12, 1:30 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
JNJ has moved up 2.38% with no identifiable headline catalyst driving the move, suggesting this could be a gap or sector rotation rather than a sustained fundamental shift. The macro context (elevated 5Y inflation breakevens at 1.9σ above trend) favors commodity and inflation-sensitive sectors like Energy and Gold, not healthcare defensives like JNJ — this could even act as a mild headwind for continuation. With 135 minutes remaining and no clear catalyst to sustain momentum, mean-reversion risk is elevated and confidence in continuation is low.
?May 12, 1:15 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
JNJ has moved up 2.23% today with no identifiable news catalyst visible in recent headlines, suggesting the move may be gap-driven or momentum-based rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not particularly favorable for healthcare/defensive names like JNJ, which are not among the sectors typically reactive to T5YIE spikes. With 150 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear catalyst and the defensive nature of the stock suggest the move may fade or stall rather than extend meaningfully into the close.
!May 12, 1:15 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
JNJ has moved up 2.23% today with no identifiable news catalyst visible in recent headlines, suggesting the move may be gap-driven or momentum-based rather than fundamentally supported. The macro context (elevated 5-year inflation expectations) is not particularly favorable for healthcare/defensive names like JNJ, which are not among the sectors typically reactive to T5YIE spikes. With 150 minutes remaining, there is time for either continuation or mean reversion, but the absence of a clear catalyst and the defensive nature of the stock suggest the move may fade or stall rather than extend meaningfully into the close.
?May 12, 1:01 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
JNJ has moved up 2.57% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting this may be a gap-up or sector rotation move rather than a fundamentally-driven continuation. The macro context (elevated 5Y inflation expectations) is more relevant to Gold, Energy, and TIPS sectors than to healthcare/consumer staples like JNJ, providing no tailwind support. With 165 minutes remaining, there is time for movement, but without a clear catalyst and the risk of mean reversion on a news-vacuum gap, the probability of continuation is below threshold.
!May 12, 1:01 PMsignalseverity 0.03
Agent VII — Day Trader — day_trade_skipped
JNJ has moved up 2.57% with no identifiable news catalyst or earnings event visible in recent headlines, suggesting this may be a gap-up or sector rotation move rather than a fundamentally-driven continuation. The macro context (elevated 5Y inflation expectations) is more relevant to Gold, Energy, and TIPS sectors than to healthcare/consumer staples like JNJ, providing no tailwind support. With 165 minutes remaining, there is time for movement, but without a clear catalyst and the risk of mean reversion on a news-vacuum gap, the probability of continuation is below threshold.
?May 12, 12:45 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
JNJ has moved up 2.49% with no identifiable catalyst from recent headlines, suggesting this may be a gap or technical move rather than news-driven momentum. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly supportive of defensive healthcare names like JNJ. With 180 minutes remaining and no clear fundamental driver, the risk of mean reversion or consolidation is elevated, making continuation uncertain.
!May 12, 12:45 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
JNJ has moved up 2.49% with no identifiable catalyst from recent headlines, suggesting this may be a gap or technical move rather than news-driven momentum. The macro context highlights elevated inflation expectations (T5YIE at 1.9σ above trend), which is not particularly supportive of defensive healthcare names like JNJ. With 180 minutes remaining and no clear fundamental driver, the risk of mean reversion or consolidation is elevated, making continuation uncertain.
?May 12, 12:30 PMdecisionconsidered
Agent VII — Day Trader — decide: skip
JNJ is up 2.23% but there is no clear earnings catalyst or major news driving today's move — the only recent headline is a conference participation announcement, which is a soft catalyst at best. With 195 minutes remaining the stock has time to move further, but the macro context (elevated 5Y inflation expectations at 1.9σ above trend) is generally unfavorable for defensive healthcare names via discount rate pressure. Without a strong identifiable catalyst, the move likely reflects sector rotation or broad market tailwinds rather than a durable stock-specific driver, making continuation uncertain.
!May 12, 12:30 PMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
JNJ is up 2.23% but there is no clear earnings catalyst or major news driving today's move — the only recent headline is a conference participation announcement, which is a soft catalyst at best. With 195 minutes remaining the stock has time to move further, but the macro context (elevated 5Y inflation expectations at 1.9σ above trend) is generally unfavorable for defensive healthcare names via discount rate pressure. Without a strong identifiable catalyst, the move likely reflects sector rotation or broad market tailwinds rather than a durable stock-specific driver, making continuation uncertain.
?May 12, 11:30 AMdecisionconsidered
Agent VII — Day Trader — decide: skip
The 2.12% move in JNJ lacks a clear intraday catalyst — the only relevant headline is a routine conference participation announcement, which is not typically a meaningful price mover. With no earnings beat, analyst upgrade, or sector-specific news driving the move, this looks more like a gap or sector rotation rather than a sustained trend. The macro context (elevated 5Y inflation expectations) is more relevant to commodities and TIPS than healthcare, providing no additional tailwind for JNJ continuation.
!May 12, 11:30 AMsignalseverity 0.02
Agent VII — Day Trader — day_trade_skipped
The 2.12% move in JNJ lacks a clear intraday catalyst — the only relevant headline is a routine conference participation announcement, which is not typically a meaningful price mover. With no earnings beat, analyst upgrade, or sector-specific news driving the move, this looks more like a gap or sector rotation rather than a sustained trend. The macro context (elevated 5Y inflation expectations) is more relevant to commodities and TIPS than healthcare, providing no additional tailwind for JNJ continuation.
❖May 11, 12:35 PMnewsvia finnhub
Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Johnson & Johnson will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9th, 2026. Management will participate in a Fireside Chat at 10:00 a.m. Eastern...
❖May 11, 12:30 PMnewsvia finnhub
Boston Scientific: Poised To Rebound With The Healthcare Sector, But When?
Boston Scientific Corporation outlook: EP share loss vs PFA leadership, Watchman & neuromod growth, improving margins and low valuation. Click for more on BSX.
❖May 11, 11:18 AMnewsvia finnhub
Merck Stock Down 7% in a Month: Should Investors Hold or Exit?
Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.
❖May 11, 10:21 AMnewsvia finnhub
Talvey (Johnson & Johnson: talquetamab-tgvs) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
Key market opportunities in the Talvey market include rising prevalence of autoimmune diseases, increasing healthcare expenditures, and expanding biosimilar development. The market is driven by personalized immunotherapy, targeted therapies, digital monitoring tools, and regional production amid tariff pressures.Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Talvey Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering
❖May 11, 8:01 AMnewsvia finnhub
FarmaMondo Group appoints Independent Board Director Natalie Douglas, global pharmaceutical managed access and commercialization pioneer
FarmaMondo Group, an international commercial pharmaceutical organization that partners with pharma and biotech to deliver innovative and specialty medicines to the 50+ emerging markets, today announces the appointment of Natalie Douglas as Independent Board Director. Douglas is best known for pioneering the managed access to commercialization drug program, now the accepted model for how the pharmaceutical industry delivers access to many international markets.
❖May 11, 8:00 AMnewsvia finnhub
Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
Johnson & Johnson (NYSE: JNJ) announced today that 18 abstracts featuring new and encore data from the Company's robust neuropsychiatry portfolio and pipeline will be presented at two upcoming scientific meetings: the American Psychiatric Association (APA) Annual Meeting (May 16-20, San Francisco) and the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (May 26-29, Miami). The presentations will highlight the Company's latest research across key neuropsychiatric disorders, i
❖May 11, 7:08 AMnewsvia finnhub
Sanofi: Great Yield And Plenty Of Upside Potential
Sanofi (SNY) stock: Strong Buy with 5.5%+ yield, undervalued multiples, and 16â20% projected returns from its robust pipelineâread the thesis here.
❖May 11, 4:10 AMnewsvia finnhub
Neurovascular Devices Global Forecast Report 2025: A $7.22 Billion Opportunity by 2030, Driven by Advancement of AI- and Robot-Assisted Systems for Next-Generation Neurointerventions
The global neurovascular devices market is projected to grow from USD 4.64 billion in 2025 to USD 7.22 billion by 2030, at a 9.3% CAGR. This growth is fueled by increased incidence of neurovascular diseases, driven by aging populations and lifestyle factors like hypertension and smoking. Demand is also propelled by technological advancements in minimally invasive procedures. Cerebral aneurysms lead the market segment with hospitals and surgical centers being primary end-users. The Asia Pacific r
❖May 10, 1:50 PMnewsvia finnhub
Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
The Goldman Sachs Retirement Survey 2025 captures a tension that runs through the entire retirement landscape. A full 68% of working respondents say they are confident they will meet their retirement goals. At the same time, 58% believe they will outlive their savings. Goldman calls this the Optimism Gap, a split between how workers feel ... Goldman Sachs Retirement Survey 2025: 58% of Americans Expect to Outlive Their Savings, and the Income Strategy That Changes the Math
❖May 10, 11:43 AMnewsvia finnhub
Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
The Goldman Sachs Retirement Survey & Insights Report 2025 puts a hard number on what many workers already sense: the bar for retirement keeps moving higher. The estimated total cost of retirement for a unisex retiree is projected to reach $2,569,000 by 2043, up from $1,747,000 in 2033. That climb reflects two forces working together. ... Goldman Sachs Retirement Survey 2025: Retirement Could Cost $2.5 Million by 2043, and Most Americans Are Not Saving Fast Enough to Keep Up
❖May 10, 10:35 AMnewsvia finnhub
2 Dividend Stocks That Are No-Brainer Buys in May
Markets are on the rise, but worries about a recession remain elevated as May gets underway.
❖May 9, 11:30 AMnewsvia finnhub
A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job
A full-time federal minimum wage worker in the United States earns $7.25 an hour, or about $15,080 a year before taxes, working 40 hours a week for 52 weeks. The question for anyone with capital: what does it take to clear that bar without having to ask anyone, “Do you want fries with that?” On ... A $500,000 Dividend Portfolio That Pays More Than a Full-Time Minimum Wage Job
❖May 9, 7:30 AMnewsvia finnhub
Johnson & Johnson CEO: America’s innovation advantage starts with health
From AI-accelerated drug discovery to a $55 billion domestic manufacturing push, the U.S. health innovation engine is just getting started.
❖May 8, 3:40 PMnewsvia finnhub
The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills the Gap
A new Nationwide Retirement Institute survey paints a stark picture: most Americans approaching retirement do not actually understand the program they are banking on. Only 21% of respondents correctly identified their full retirement age based on their year of birth, and the average adult answered just 8 of 15 true-or-false questions about Social Security correctly. ... The Nationwide Social Security Survey Says Most Americans Are Flying Blind on Benefits, Here’s the Income Strategy That Fills t
❖May 8, 12:41 PMnewsvia finnhub
Nationwide Survey: 83% of Americans Are Worried Social Security Won’t Survive, and Here’s What to Do About It
The fear is loud, and the data backs it up. According to the Nationwide Retirement Institute’s 2025 Social Security Survey, 83% of Americans currently receiving or expecting to receive Social Security are concerned about the program’s future. That worry is not happening in a vacuum. The Social Security Administration’s own trustees project that the Old-Age ... Nationwide Survey: 83% of Americans Are Worried Social Security Won’t Survive, and Here’s What to Do About It
❖May 8, 8:20 AMnewsvia finnhub
3 Unstoppable Dividend King Stocks to Buy Right Now for Less Than $550
These companies pay some of the world's most bankable dividends.
❖May 8, 7:50 AMnewsvia finnhub
Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold
Warren Buffett stepped down as CEO of Berkshire Hathaway (BRK-B) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: more than 65% of Berkshire’s $381 billion portfolio is ... Warren Buffett and Berkshire Hathaway Own 2 Dividend Kings That Will Never Be Sold
❖May 7, 2:46 PMnewsvia finnhub
DARZALEX royalties drive Genmab’s Q1 revenue higher amid expansion push
Investing.com -- Genmab reported a 25% year-on-year increase in first-quarter revenue for 2026, driven by strong royalty income from blockbuster cancer drug DARZALEX and multiple sclerosis treatment Kesimpta, as the Danish biotech company continued investing heavily in its late-stage oncology pipeline.
❖May 7, 1:13 PMnewsvia finnhub
Johnson And Johnson Balances Mental Health Push With Mixed Pipeline Outlook
Johnson & Johnson (NYSE:JNJ) has launched its global "Generation Fine" campaign to address depression care and improve patient conversations. The company reported new FDA approvals and positive Phase 3 data in immunology and neuropsychiatry, alongside progress on its OTTAVA robotic surgery platform. JNJ outlined an accelerated global registration plan for JNJ-1900 in head and neck cancer. The dual target antibody JNJ-4804 for inflammatory bowel disease did not meet its main Phase 2b...
❖May 7, 11:42 AMnewsvia finnhub
Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1
Darzalex and new launches fuel J&J's 17.8% oncology sales growth in Q1 as the company targets $50B in cancer sales by 2030.
❖May 7, 11:34 AMnewsvia finnhub
Why This Income Pro Likes Banks, Chip-Equipment Companies, and More
Michael Barclay, lead manager of the Columbia Dividend Income fund, favors dividend growers over high yields.
❖May 7, 8:00 AMnewsvia finnhub
Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare provider. Informed by a global survey of patients and healthcare providers spanning seven countries and four continents, the campaign reflects a troubling reality: nearly 4 in 5 patients living with major depressive disorder (M
❖May 7, 4:52 AMnewsvia finnhub
Lilly, Gilead lead pharma’s M&A boom
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.
❖May 7, 2:09 AMnewsvia finnhub
Breach Of Contract, IP Rights, And Irreparable Harm: Lessons From The Third Circuit’s Stelara Decision
Johnson & Johnson et al. v. Samsung Bioepis Co. Ltd., No. 25-1831 The Third Circuit affirmed denial of an injunction to prevent a biosimilar manufacturer from launching a biosimilar version of the...
❖May 7, 1:33 AMnewsvia finnhub
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sites
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments.
❖May 6, 4:20 PMnewsvia finnhub
Safer Dividend King to Buy Now: AbbVie or Johnson & Johnson?
They have combined for 118 years of consecutive dividend increases.
❖May 6, 2:34 PMnewsvia finnhub
J & J Snack Foods Q2 Earnings Call Highlights
J & J Snack Foods (NASDAQ:JJSF) reported fiscal second-quarter 2026 results that showed margin expansion and higher adjusted earnings despite a decline in sales, as management pointed to benefits from its “Project Apollo” transformation and ongoing portfolio reshaping. Chief Executive Officer D
❖May 6, 2:03 PMnewsvia finnhub
Is Johnson & Johnson Still the Ultimate Safe Dividend Stock to Buy?
It's hard to argue against its reliability.
❖May 6, 10:32 AMnewsvia finnhub
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can be redeployed or spent without selling property or waiting on private placements. Pharma is one of the few sectors where mature franchises, regulatory ... 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash
❖May 6, 9:50 AMnewsvia finnhub
These 3 Dividend Stocks Have Raised Their Payouts for a Combined 187 Years. Here’s Why That Matters To Passive Income Lovers
Earned income disappears the moment you stop working. Dividend income keeps arriving every quarter. That distinction drives serious investors toward portfolios built around cash-generative businesses with multi-decade payout histories, where the check arrives every quarter regardless of market conditions. Starting fresh today, the temptation is to chase double-digit yields from leveraged BDCs and mortgage REITs. ... These 3 Dividend Stocks Have Raised Their Payouts for a Combined 187 Years. Here
❖May 6, 9:15 AMnewsvia finnhub
Can Pfizer Stock Outrun A $17B Revenue Void?
The true narrative for Pfizer (PFE) is not its recent top line earnings beat but the escalating structural tension between its required research spending and an impending revenue void. First quarter 2026 results showed an adjusted earnings per share of $0.75 on $14.5 billion in revenue. While these numbers exceeded consensus estimates, they mask a deeper profitability issue. The primary insight hiding within the earnings noise is that Pfizer is funding its future growth at the direct expense of
❖May 6, 8:37 AMnewsvia finnhub
CVS Health's Lower Medical Cost Ratio Lift Profit, Outlook
CVS Health Q1 tops estimates, lifts 2026 outlook, and sees gains in Health Care Benefits and Health Services segments.
❖May 6, 7:00 AMnewsvia finnhub
Royalty Pharma reports first quarter 2026 results
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma has delivered a strong start to 2026 across multi
❖May 6, 6:30 AMnewsvia finnhub
Avalo shares spike on skin drug data; BioNTech to cut staff
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
❖May 6, 5:50 AMnewsvia finnhub
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report
White House estimates Trump's drug pricing agreements could save $529 billion in next decade, but analysis draws scrutiny.
❖May 6, 3:00 AMnewsvia finnhub
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech sees as a differentiated option for patients with persistent disease.
❖May 6, 12:57 AMnewsvia finnhub
Male Labor Force Participation Slumps As US Job Growth Tilts Toward Healthcare
Widening gap in male labor force participation is signaling deeper shifts in US economy, as job growth concentrates in healthcare.
❖May 5, 7:30 PMnewsvia finnhub
As American Water Works Hikes Its Dividend, Consider Buying AWK Stock in May
The broader investment case rests on AWK's 19-year dividend growth streak, a 5-year average dividend growth rate of about 9%, and a pending merger with Essential Utilities that would make it the largest U.S. water utility with over 4.7 million connections.
❖May 5, 7:25 PMnewsvia finnhub
Robert F. Kennedy Jr. Wants To Take 'Clear And Decisive Action' On Psychiatric Drugs Amid 'Deprescribing' Push: Big Pharma Should Pay Attention
Robert F. Kennedy Jr. unveiled a federal initiative to curb the overuse of psychiatric medications, emphasizing deprescribing and a shift toward preventive, patient-centered mental health care.
❖May 5, 4:20 PMnewsvia finnhub
SOPHiA GENETICS Q1 Earnings Call Highlights
SOPHiA GENETICS (NASDAQ:SOPH) reported first-quarter 2026 revenue of $21.7 million, up 22% from $17.8 million in the prior-year period, as demand increased for its SOPHiA DDM analytics platform and the company expanded its installed base of clinical customers and applications. Revenue growth and re
❖May 5, 2:05 PMnewsvia finnhub
Final Trade: DAL, HNGE, Mag 7, JNJ
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
❖May 5, 1:57 PMnewsvia finnhub
Protagonist Therapeutics CEO on earnings, commercialization, and partnerships
Dinesh Patel, Protagonist Therapeutics CEO, joins 'Fast Money' to talk earnings, commercialization, and partnerships.
❖May 5, 1:45 PMnewsvia finnhub
27% of Americans Own ETFs but Allocate Just 6%, Here’s Why That Costs Them Retirement Income
The Charles Schwab Modern Wealth Survey 2025 found that 27% of American investors own ETFs, yet those funds account for only 6% of the average portfolio. Individual stocks: 25%; mutual funds: 13%; cryptocurrency: 10%. The mismatch matters most for pre-retirees, because dividend-focused ETFs package the income-producing equity asset class into a single low-cost holding that ... 27% of Americans Own ETFs but Allocate Just 6%, Here’s Why That Costs Them Retirement Income
❖May 5, 12:56 PMnewsvia finnhub
J&J’s soft tissue surgical robot succeeds in pivotal gastric bypass study
The medtech giant hopes to bolster its position in the growing surgical robotics market, which is currently dominated by Intuitive Surgical.
❖May 5, 11:15 AMnewsvia finnhub
Johnson And Johnson Expands Clinical Pipeline In Immunology MedTech And AI
Johnson & Johnson (NYSE:JNJ) reported new clinical results in immunology, MedTech, and neuropsychiatry. The company announced pivotal Phase 3 data for TREMFYA in perianal fistulizing Crohn’s disease, the first successful randomized trial in this area in 20 years. Johnson & Johnson shared results for JNJ-4804 in highly refractory ulcerative colitis and Crohn’s disease, supporting expanded Phase 3 programs. In MedTech, the company released first-in-human data for the OTTAVA Robotic Surgical...
❖May 5, 10:50 AMnewsvia finnhub
Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter
Passive income is the cash flow that arrives whether you are working, sleeping, or watching the market churn. For investors who have spent decades building a paycheck, the appeal of a portfolio that pays you on a fixed schedule is less about getting rich and more about getting reliable. Earned income stops the moment you ... Put $5,000 Into This Dividend Giant and Earn Passive Income Every Quarter
❖May 5, 10:41 AMnewsvia finnhub
'F.D.A. Blocked Publication of Research Finding Covid and Shingles Vaccines Were Safe' - The New York Times
https://www.nytimes.com/2026/05/05/us/politics/fda-covid-vaccine-studies.html
❖May 5, 9:00 AMnewsvia finnhub
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
❖May 5, 9:00 AMnewsvia finnhub
Model N Appoints Thomas Gibbs to Board of Directors
Seasoned pharmaceutical executive brings over 25 years of commercial leadership to Model N boardREDWOOD CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Model N, a leading end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced the appointment of Thomas Gibbs to the company’s board of directors. Gibbs has over 25 years of leadership experience across Executive Management, Marketing, Sales, Commercial Operations, and Finance at small, mid-s
❖May 5, 9:00 AMnewsvia finnhub
Zifo's SiEE Boston Summit Charts New Roadmap for 'Practical AI' in Life Sciences, Bridging the Gap Between Business Vision and Lab Reality
Trading the abstract allure of AI hype for a technical implementation roadmap, Zifo's 2026 Scientific Informatics Experience Exchange (SiEE) in Boston concluded with heavyweights from Sanofi, Takeda, AbbVie, Regeneron, Biogen, Eli Lilly, Novo Nordisk, J&J, and Broad Institute establishing that the industry's digital future now rests on the 'first mile' of lab data integrity.

← Back to dashboard